<H1>Chapter DOI: 10.1007/s12032-016-0791-3<br/>Cited-By Count: 0</H1><table border="1" width="30%"><tr><td>Total References</td><td>33</td></tr><tr><td>Springer references</td><td>4</td></tr><tr><td>Non Springer references</td><td>29</td></tr><tr><td>BibStructured Count</td><td width="10%">33</td></tr><tr><td>BibUnstructured Count</td><td width="10%">0</td></tr><tr><td>DOI already available in SpringerLink</td><td>26</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>2</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>2</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>2</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1</td><td>BibArticle</td><td>Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69&#8211;90.</td><td><a href=http://dx.doi.org/10.3322/caac.20107>10.3322/caac.20107</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2</td><td>BibArticle</td><td>Hassanein M, Callison JC, Callaway-Lane C, Aldrich MC, Grogan EL, Massion PP. The state of molecular biomarkers for the early detection of lung cancer. Cancer Prev Res (Phila). 2012;5:992&#8211;1006.</td><td><a href=http://dx.doi.org/10.1158/1940-6207.CAPR-11-0441>10.1158/1940-6207.CAPR-11-0441</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR3</td><td>BibArticle</td><td>Hesson LB, Cooper WN, Latif F. Evaluation of the 3p21.3 tumour-suppressor gene cluster. Oncogene. 2007;26:7283&#8211;301.</td><td><a href=http://dx.doi.org/10.1038/sj.onc.1210547>10.1038/sj.onc.1210547</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4</td><td>BibArticle</td><td>Lerman MI, Minna JD. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The international lung cancer chromosome 3p21.3 tumor suppressor gene consortium. Cancer Res. 2000;60:6116&#8211;33.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR5</td><td>BibArticle</td><td>Wistuba II, Behrens C, Virmani AK, Mele G, Milchgrub S, Girard L, et al. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res. 2000;60:1949&#8211;60.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR6</td><td>BibArticle</td><td>Senchenko VN, Liu J, Loginov W, Bazov I, Angeloni D, Seryogin Y, et al. Discovery of frequent homozygous deletions in chromosome 3p21.3 LUCA and AP20 regions in renal, lung and breast carcinomas. Oncogene. 2004;23:5719&#8211;28.</td><td><a href=http://dx.doi.org/10.1038/sj.onc.1207760>10.1038/sj.onc.1207760</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7</td><td>BibArticle</td><td>Dmitriev AA, Kashuba VI, Haraldson K, Senchenko VN, Pavlova TV, Kudryavtseva AV, et al. Genetic and epigenetic analysis of non-small cell lung cancer with NotI-microarrays. Epigenetics. 2012;7:502&#8211;13.</td><td><a href=http://dx.doi.org/10.4161/epi.19801>10.4161/epi.19801</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR8</td><td>BibArticle</td><td>Zabarovsky ER, Lerman MI, Minna JD. Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene. 2002;21:6915&#8211;35.</td><td><a href=http://dx.doi.org/10.1038/sj.onc.1205835>10.1038/sj.onc.1205835</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9</td><td>BibArticle</td><td>Pastuszak-Lewandoska D, Kordiak J, Migdalska-S&#281;k M, Czarnecka KH, Antczak A, G&#243;rski P, et al. Quantitative analysis of mRNA expression levels and DNA methylation profiles of three neighboring genes: FUS1, NPRL2/G21 and RASSF1A in non-small cell lung cancer patients. Respir Res. 2015;16:76.</td><td><a href=http://dx.doi.org/10.1186/s12931-015-0230-6>10.1186/s12931-015-0230-6</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR10</td><td>BibArticle</td><td>Esteller M. Epigenetics in cancer. N Engl J Med. 2008;358:1148&#8211;59.</td><td><a href=http://dx.doi.org/10.1056/NEJMra072067>10.1056/NEJMra072067</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11</td><td>BibArticle</td><td>Burbee DG, Forgacs E, Z&#246;chbauer-M&#252;ller S, Shivakumar L, Fong K, Gao B, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst. 2001;93:691&#8211;9.</td><td><a href=http://dx.doi.org/10.1093/jnci/93.9.691>10.1093/jnci/93.9.691</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12</td><td>BibArticle</td><td>Toyooka S, Suzuki M, Maruyama R, Toyooka KO, Tsukuda K, Fukuyama Y, et al. The relationship between aberrant methylation and survival in non-small-cell lung cancers. Br J Cancer. 2004;91:771&#8211;4.</td><td><a href=http://dx.doi.org/10.1038/sj.bjc.6602013>10.1038/sj.bjc.6602013</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, ArticleTitle, Year, JournalTitle, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR13</td><td>BibArticle</td><td>Z&#246;chbauer-M&#252;ller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res. 2001;61:249&#8211;55.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR14</td><td>BibArticle</td><td>Heller G, Zielinski CC, Z&#246;chbauer-M&#252;ller S. Lung cancer: from single-gene methylation to methylome profiling. Cancer Metastasis Rev. 2010;29:95&#8211;107.</td><td><a href=http://dx.doi.org/10.1007/s10555-010-9203-x>10.1007/s10555-010-9203-x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15</td><td>BibArticle</td><td>Feltus FA, Lee EK, Costello JF, Plass C, Vertino PM. Predicting aberrant CpG island methylation. Proc Natl Acad Sci USA. 2003;100:12253&#8211;8.</td><td><a href=http://dx.doi.org/10.1073/pnas.2037852100>10.1073/pnas.2037852100</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR16</td><td>BibArticle</td><td>Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics. 2002;18:1427&#8211;31.</td><td><a href=http://dx.doi.org/10.1093/bioinformatics/18.11.1427>10.1093/bioinformatics/18.11.1427</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR17</td><td>BibArticle</td><td>Liloglou T, Bediaga NG, Brown BR, Field JK, Davies MP. Epigenetic biomarkers in lung cancer. Cancer Lett. 2014;342:200&#8211;12.</td><td><a href=http://dx.doi.org/10.1016/j.canlet.2012.04.018>10.1016/j.canlet.2012.04.018</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR18</td><td>BibArticle</td><td>Zhang Y, Miao Y, Yi J, Wang R, Chen L. Frequent epigenetic inactivation of deleted in lung and esophageal cancer 1 gene by promoter methylation in non-small-cell lung cancer. Clin Lung Cancer. 2010;11:264&#8211;70.</td><td><a href=http://dx.doi.org/10.3816/CLC.2010.n.034>10.3816/CLC.2010.n.034</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR19</td><td>BibArticle</td><td>Rauch T, Li H, Wu X, Pfeifer GP. MIRA-assisted microarray analysis, a new technology for the determination of DNA methylation patterns, identifies frequent methylation of homeodomain- containing genes in lung cancer cells. Cancer Res. 2006;66:7939&#8211;47.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-06-1888>10.1158/0008-5472.CAN-06-1888</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR20</td><td>BibArticle</td><td>Seng TJ, Currey N, Cooper WA, Lee CS, Chan C, Horvath L, et al. DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma. Br J Cancer. 2008;99:375&#8211;82.</td><td><a href=http://dx.doi.org/10.1038/sj.bjc.6604452>10.1038/sj.bjc.6604452</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR21</td><td>BibArticle</td><td>Sasaki H, Hikosaka Y, Kawano O, Moriyama S, Yano M, Fujii Y. Methylation of the DLEC1 gene correlates with poor prognosis in Japanese lung cancer patients. Oncol Lett. 2010;1:283&#8211;7.</td><td><a href=http://dx.doi.org/10.3892/ol_00000050>10.3892/ol_00000050</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, ArticleTitle, Year, VolumeID</td><td>CrossRef</td></tr><tr><td>CR22</td><td>BibArticle</td><td>Anedchenko EA, Dmitriev AA, Krasnov GS, Kondrat&#8217;eva TT, Kopantsev EP, Vinogradova TV, et al. Down-regulation of RBSP3/CTDSPL, NPRL2/G21, RASSF1A, ITGA9, HYAL1 and HYAL2 genes in non-small cell lung cancer. Mol Biol (Mosk). 2008;42:965&#8211;76.</td><td><a href=http://dx.doi.org/10.1134/S0026893308060058>10.1134/S0026893308060058</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR23</td><td>BibArticle</td><td>H&#248;ye AM, Couchman JR, Wewer UM, Fukami K, Yoneda A. The newcomer in the integrin family: integrin &#945;9 in biology and cancer. Adv Biol Regul. 2012;52:326&#8211;39.</td><td><a href=http://dx.doi.org/10.1016/j.jbior.2012.03.004>10.1016/j.jbior.2012.03.004</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR24</td><td>BibArticle</td><td>Hibi K, Yamakawa K, Ueda R, Horio Y, Murata Y, Tamari M, et al. Aberrant upregulation of a novel integrin alpha subunit gene at 3p21.3 in small cell lung cancer. Oncogene. 1994;9:611&#8211;9.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR25</td><td>BibArticle</td><td>Mostovich LA, Prudnikova TY, Kondratov AG, Loginova D, Vavilov PV, Rykova VI, et al. Integrin alpha9 (ITGA9) expression and epigenetic silencing in human breast tumors. Cell Adhes Migr. 2011;5:395&#8211;401.</td><td><a href=http://dx.doi.org/10.4161/cam.5.5.17949>10.4161/cam.5.5.17949</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR26</td><td>BibArticle</td><td>Geng X, Wang F, Zhang L, Zhang WM. Loss of heterozygosity combined with promoter hypermethylation, the main mechanism of human MutL Homolog (hMLH1) gene inactivation in non-small cell lung cancer in a Chinese population. Tumori. 2009;95:488&#8211;94.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR27</td><td>BibArticle</td><td>Bischoff J, Ignatov A, Semczuk A, Schwarzenau C, Ignatov T, Krebs T, et al. hMLH1 promoter hypermethylation and MSI status in human endometrial carcinomas with and without metastases. Clin Exp Metastasis. 2012;29:889&#8211;900.</td><td><a href=http://dx.doi.org/10.1007/s10585-012-9478-0>10.1007/s10585-012-9478-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR28</td><td>BibArticle</td><td>Safar AM, Spencer H 3rd, Su X, Coffey M, Cooney CA, Ratnasinghe LD, et al. Methylation profiling of archived non-small cell lung cancer: a promising prognostic system. Clin Cancer Res. 2005;11:4400&#8211;5.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-04-2378>10.1158/1078-0432.CCR-04-2378</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR29</td><td>BibArticle</td><td>Tang M, Torres-Lanzas J, Lopez-Rios F, Esteller M, Sanchez-Cespedes M. Wnt signaling promoter hypermethylation distinguishes lung primary adenocarcinomas from colorectal metastasis to the lung. Int J Cancer. 2006;119:2603&#8211;9.</td><td><a href=http://dx.doi.org/10.1002/ijc.22211>10.1002/ijc.22211</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR30</td><td>BibArticle</td><td>Wang YC, Lu YP, Tseng RC, Lin RK, Chang JW, Chen JT, et al. Inactivation of hMLH1 and hMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples. J Clin Invest. 2003;111:887&#8211;95.</td><td><a href=http://dx.doi.org/10.1172/JCI15475>10.1172/JCI15475</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR31</td><td>BibArticle</td><td>Hsu HS, Wen CK, Tang YA, Lin RK, Li WY, Hsu WH, et al. Promoter hypermethylation is the predominant mechanism in hMLH1 and hMSH2 deregulation and is a poor prognostic factor in nonsmoking lung cancer. Clin Cancer Res. 2005;11:5410&#8211;6.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-05-0601>10.1158/1078-0432.CCR-05-0601</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR32</td><td>BibArticle</td><td>Gomes A, Reis-Silva M, Alarc&#227;o A, Couceiro P, Sousa V, Carvalho L. Promoter hypermethylation of DNA repair genes MLH1 and MSH2 in adenocarcinomas and squamous cell carcinomas of the lung. Rev Port Pneumol. 2014;20:20&#8211;30.</td><td><a href=http://dx.doi.org/10.1016/j.rppneu.2013.07.003>10.1016/j.rppneu.2013.07.003</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR33</td><td>BibArticle</td><td>Li M, Zhang Q, Liu L, Lu W, Wei H, Li RW, et al. Expression of the mismatch repair gene hMLH1 is enhanced in non-small cell lung cancer with EGFR mutations. PLoS One. 2013;8:e78500.</td><td><a href=http://dx.doi.org/10.1371/journal.pone.0078500>10.1371/journal.pone.0078500</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>